Sarepta Lifts 2026 Revenue Guidance Floor by $50M as ELEVIDYS Slides
SRPT sits 22% above its 52-week low of $14.68.
Summary
Sarepta posted Q3 2026 revenue of $381.4 million, down 5%, as ELEVIDYS US sales fell 37% to $83.5 million. It raised the low end of 2026 product revenue guidance by $50.0 million and trimmed the high end of expense guidance by $25.0 million. DM1 and FSHD multiple ascending dose data is expected in Q4 2026.
Key Events · Earnings and Guidance · SRPT
-
Q3 Revenue Falls 5% to $381.4M
Total revenues were $381.4 million versus $399.4 million a year earlier. ELEVIDYS US net product revenue dropped 37% to $83.5 million under the ambulatory-only label, while PMO net product revenue of about $240.3 million offset the decline.
-
Guidance Raised at the Low End
Sarepta raised the low end of full-year total net product revenue guidance by $50.0 million to a $1.25 billion to $1.3 billion range. It also lowered the high end of combined non-GAAP R&D and SG&A expense guidance by $25.0 million to $800-825 million.
-
Non-GAAP Profit and Positive Cash Flow
Q3 2026 non-GAAP operating income was $22.9 million versus a $35.7 million loss a year ago. The company ended the quarter with $998.7 million in cash, cash equivalents, restricted cash and investments.
-
$62M Catalent Take-or-Pay Charge
GAAP net loss was $28.5 million (-$0.27 per share). Cost of sales of $188.5 million included a $62.0 million take-or-pay charge for Catalent inventories Sarepta elected not to manufacture.
Analysis · SRPT · Life Sciences
The quarter tells two stories at once. ELEVIDYS US sales fell 37% to $83.5 million under the narrowed ambulatory-only label, yet the PMO franchise carried the period at roughly $240.3 million. Management raised the low end of full-year product revenue guidance by $50.0 million to $1.25-1.3 billion and cut the high end of expense guidance by $25.0 million. Sarepta also swung to non-GAAP operating income of $22.9 million and positive cash flow, ending with $998.7 million in cash, which funds the DM1 and FSHD programs. Those programs are the real swing factor: multiple ascending dose data for SRP-1003 and SRP-1001 is expected in Q4 2026, and Sarepta says it is already preparing Phase 3 manufacturing. A $28.5 million GAAP net loss (-$0.27 per share) includes a $62.0 million Catalent take-or-pay charge for inventory it elected not to manufacture.
How filings like this one have moved
In the 30 days to Nov 17, 2026, 48.3% of the 2133 measured filings Wiseek scored 8 moved their stock by 5% or more by the next session's close. The median move was -0.28%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, SRPT was trading at $17.93 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $1.9B. The 52-week trading range was $14.68 to $24.68. This filing was assessed with neutral market sentiment and an importance score of 8 out of 10.